Therapeutic response and safety of different treatments for cutaneous leishmaniasis in patients: A retrospective cross-sectional study

Abstract

Objective: To analyze the therapeutic response and safety of different treatments for cutaneous leishmaniasis, received by patients in the Program for the Study and Control of Tropical Diseases-PECET-Medellín-Colombia. Methods: This is a retrospective cross-sectional study of patients attended at PECET Research Center during 2016-2021. Relevant information regarding sociodemographic characteristics, history of leishmaniasis, characterization of current infection, treatment received, follow-up of therapeutic response and safety was collected from the medical records. Data were analyzed with Pearson's Chi-square association tests and Mann-Whitney U test using statistical software. Results: A total of 486 clinical records of patients were analyzed, and 356 received treatment. Eight different therapeutic alternatives (systemic, local and in combination) were analyzed. The therapeutic response of the different alternatives used (except thermotherapy) was higher than 50%. Most frequent adverse events were myalgias, arthralgias and headache, and vesicles for systemic and local treatment, respectively. Conclusions: Safety profile and performance of local therapeutic alternatives and combined schemes for the treatment of uncomplicated cutaneous leishmaniasis are an interesting option for the management of the disease.

Keywords

Cutaneous leishmaniasis / Systemic treatment / Local treatment / Combined treatment / Tropical neglected disease / Safety / Therapeutic response

References

[1] Organización Panamericana de la Salud. Manual de procedimientos para vigilancia y control de las leishmaniasis en las Américas. Washington, D.C.: OPS; 2019.

[2] Goto H, Lauletta Lindoso JA. Cutaneous and mucocutaneous leishmaniasis. Infect Dis Clin North Am 2012; 26(2):293-307.

[3] Ministerio de Salud de Colombia. Lineamientos para la atención clínica de leishmaniasis en Colombia. Bogotá, 2018. [Online]. Disponible en:https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/PAI/Lineamientos-leishmaniasis.pdf. [Accessed on 1 March 2021].

[4] Bailey MS, Lockwood DNJ. Cutaneous leishmaniasis. Clin Dermatol 2007; 25(2):203-211.

[5] World Health Organization. Leishmaniasis. [Online]. Available from:https://www.who.int/es/news-room/fact-sheets/detail/leishmaniasis. [Accessed on 1 March2021].

[6] Pinart M, Rueda JR, Romero GAS, Pinzón-Flórez CE, Osorio-Arango K, Silveira Maia-Elkhoury AN, et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2009; 2020; 8:14.

[7] Organización Panamericana de la Salud. Leishmaniasis: Informe epidemiológico de las Américas. Núm. 10, diciembre del 2021. Washington, D.C.: OPS; 2021. [Online]. Disponible en:https://iris.paho.org/handle/10665.2/51742. [Accessed on 1 March 2021].

[8] World Health Organization. Control de las leishmaniasis Informe. Control las leishmaniasis Inf una Reun del Com Expert la OMS sobre el Control las Leishmaniasis, Ginebra, 22-26 marzo 2010, 2010; p.186. [Online]. Disponible en:https://apps.who.int/iris/bitstream/handle/10665/82766/WHO_TRS_949_spa.pdf?sequence=1. [Accessed on 1 March 2021].

[9] Henao HH, Osorio Y, Saravia NG, Gómez A, Travi B. Eficacia y toxicidad de los antimoniales pentavalentes (Glucantime y Pentostam) en un modelo animal de leishmaniasis cutánea americana: Aplicación de la luminometría. Biomédica 2004; 24(4):393.

[10] Vásquez de Ricciardi Laura. Terapéutica antileishmania: revisando el pasado, el presente y el futuro. Gac Méd Caracas 2009; 117(2):93-111. [Online]. Disponible en:http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0367-47622009000200002. [Accessed on 1 March 2021].

[11] Limachi-Choque JW, Rojas-Cabrera E, Verduguez-Orellana A, Eid-Rodríguez D. El tratamiento intralesional de Leishmaniasis cutánea es seguro frente al riesgo de complicaciones mucosas? Gac Medica Boliv 2020; 43(1):18-22.

[12] Soto J, Soto P. Oral miltefosine to treat leishmaniasis. Biomedica 2006; 26(Suppl 1):207-217.

[13] Robledo SM, Puerta JA, Muñoz DL, Guardo M, Vélez ID. Efficacy and tolerance of pentamidine for treatment of cutaneous leishmaniasis caused by por L. (V) panamensis in Colombia. Biomedica 2006; 26(Suppl 1):188-193.

[14] Medina-Morales DA, Machado-Duque ME, Machado-Alba JE. Epidemiology of cutaneous leishmaniasis in a colombian municipality. Am J Trop Med Hyg 2017; 97(5):1503-1507. doi: 10.4269/ajtmh.17-0233. Epub 2017 Aug 18. PMID: 28820714; PMCID: PMC5817762.

[15] Blanco VM, Cossio A, Martinez JD, Saravia NG. Clinical and epidemiologic profile of cutaneous leishmaniasis in Colombian children: Considerations for local treatment. Am J Trop Med Hyg 2013; 89(2):359-364. doi: 10.4269/ajtmh.12-0784. Epub 2013 Jun 24. PMID: 23798581; PMCID: PMC3741260.

[16] López L, Robayo M, Vargas M, Vélez ID. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. Trials 2012; 13:58. Erratum in: Trials 2017; 18(1): 408.

[17] Robledo Restrepo SM, Quintero J, Higuita J, Fernández M, Murillo J, Restrepo A, et al. Caesalpinia spinosa (Molina) Kuntze: Una nueva promesa para el tratamiento tópico de la leishmaniasis cutánea. Rev Acad Colomb Cienc Exactas Fis Nat 2020; 44(173):915-936.

[18] Robledo Restrepo S, Vélez Bernal I, Pantoja Sánchez H, Higuita Castro J. Hidrogel que comprende acrilamida y ácido acrílico para el tratamiento de leishmaniasis cutánea. NC2017/0004890 (patent) 2020.

[19] López L, Valencia B, Alvarez F, Ramos AP, Llanos-Cuentas A, Echevarria J, et al. A phase II multicenter randomized study to evaluate the safety and efficacy of combining thermotherapy and a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New World. PLoS Negl Trop Dis 2022; 16(3):e0010238.

[20] Pan American Health Organization. Guideline for the treatment of leishmaniasis in the Americas. 2nd edition [Online]. Washington, D.C.:Pan American Health Organization ; 2022. [Online]. Available from:https://iris.paho.org/bitstream/handle/10665.2/56120/9789275125038_eng.pdf?sequence=13&isAllowed=y. [Accessed on 1 March 2023].

[21] World Health Organization. Control of leishmaniasis, 2007. [Online]. Available from:https://apps.who.int/gb/ebwha/pdf_files/WHA60/A60_10-en.pdf. [Accessed on 1 March 2021].

[22] Vélez I, López L, Sánchez X, Mestra L, Rojas C, Rodríguez E. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83(2):351-356.

[23] Cardona-Arias JA, Vélez ID, López-Carvajal L. Efficacy of thermotherapy to treat cutaneous leishmaniasis: A meta-analysis of controlled clinical trials. PLoS One 2015; 10(5):e0122569.

[24] Vélez ID, Muskus C, Robledo SM. An updated geographical distribution of Leishmania species involved in human leishmaniasis in Colombia. 2021. [Online]. Available from:https://doi.org/10.21203/rs.3.rs-200484/v1. [Accessed on 1 March 2021].

[25] Vélez I, López L, Sánchez X, Mestra L, Rojas C, Rodríguez E. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83(2):351-356.